BCR-ABL1 и ABL1 - QuantideX® qPCR BCR-ABL IS transcript analysis kit for monitoring chronic myeloid leukemia, Asuragen, USA.

Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.

Features & Benefits

• Direct reporting on the International Scale (IS): No sample exchange or conversion factor calculations required
• Data analysis software eliminates manual intervention to provide automated calculations and streamlined reporting
• Limit of Detection (LOD) of MR4.7 (0.002%IS): 95% detection at LOD as determined using human RNA specimens
• Increased analytical sensitivity without compromising analytical specificity: Non-CML (major) transcripts not detected in assay
• Armored RNA®-based standards providing true RNA quantification for a quantitative RNA assay
• Robust performance as indicated by minimum variability of replicate measurements

  To get the price of  BCR-ABL1 та ABL-1 - QuantideX® qPCR BCR-ABL IS and professional advice in selection of equipment, please, contact our consultants in any way convenient for you.

For more information about BCR-ABL1 та ABL-1 - QuantideX® qPCR BCR-ABL IS   cryostorages visit manufacturer's website